Pharma Digest

Opinion: AI could revolutionize antibiotics — but the market is standing in the way Third Way Health Secures $15M to Streamline Front-Office Operations for Medical Practices In­vestors are pump­ing mon­ey in­to AI tools for health in­sur­ers

UCB enters TCE space with $1.1B deal for Chinese biotech's autoimmune candidate New cancer cases prompt Kyowa to discontinue late‑stage autoimmune disease program FDA details rationale for rejecting rare disease gene therapy from Regenxbio

STAT+: FDA grants breakthrough status to generative AI chatbot AI Startups ROI Reckoning: What 4 VCs Say Matters Now Actionable AI in Clinical Settings: Trust and Transparency as the Core Operating System

[AI Generated Biotech and Pharma News] Ascendis wins FDA approval of dwarfism drug Lynk points to phase 3 eczema win as more proof of next-gen JAK inhibitor's potential Novo Nordisk teams with Langer-founded biotech for oral obesity drugs

Senhwa's CX-4945 targets CK2 kinase with dual tumor and immune modulatory mechanisms; CellType's AI platform aims to expand indications and improve clinical success via multi-omics analysis and translational validation. Generate's $400M IPO signals strong investor confidence, driven by AI-designed pipelines including GB-0895, an AI-optimized TSLP inhibitor with potential to disrupt ast...

BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates

[AI Generated AI in Pharma News] Lilly debuts Nvidia supercomputer with fanfare and focus on escaping traditional pharma lifecycle Earendil pens $885M pact to use WuXi XDC's linker tech for next-gen ADCs XtalPi's AI + Robotics Platform Powers First Clinical Milestone for ReviR's Rare Neurological Drug RTX-117

[AI Generated Pharma and Biotech News] United Therapeutics' phase 3 win tees up filing to challenge J&J in cardiac condition FDA fully releases clinical hold on Intellia CRISPR gene therapy Earendil pens $885M pact to use WuXi XDC's linker tech for next-gen ADCs

[AI Generated AI in Pharma and Biotech News] QScreen AI secured CAD 500,000 in financing to expand its AI and quantum-driven health screening solutions across North America and Mexico. Investment is surging in the health insurance sector, highlighted by Handl Health’s $14.2 million Series A funding for AI tools that streamline underwriting and claims management. Roche and Insilico Medicine (in col...

[AI Generated Pharma News] Earendil Labs and WuXi XDC have partnered to integrate machine learning with the WuXiTecan-2 platform to optimize the design and targeting precision of antibody-drug conjugates (ADCs). ImmVira is expanding clinical trials for MVR-T3011, a genetically engineered oncolytic virus, to treat BCG-naïve bladder cancer patients as a dual-action alternative to traditional therapi...

[AI Generated Pharma News] Pfizer has acquired the Chinese commercialization rights for Sciwind’s GLP-1 drug, ecnoglutide, in a deal valued at up to $495 million to target the region's growing metabolic disorder market. GSK is expanding its respiratory and cardiovascular pipeline through a $950 million acquisition of 35Pharma, gaining access to a promising activin signaling inhibitor for pulmo...

[AI Generated AI in Drug Discovery News] Dimension has secured $500 million to fund approximately 24 companies, aiming to integrate computational power with life sciences to accelerate drug discovery. The BiopharmaTrend 2026 watchlist identifies startups founded in 2021 that are using AI platforms to move away from single-asset strategies toward more precise, platform-based drug development. Y Com...

[AI Generated AI in Drug Discovery News] Turbine is utilizing a recently secured $25 million in Series B funding to advance its "lab-in-the-loop" AI platform that simulates biological processes to reduce the cost and risk of drug discovery. Evinova has established strategic partnerships with AstraZeneca, Astellas, and Bristol Myers Squibb to integrate AI across the drug development spect...

[AI generated Pharma News] Turbine's Virtual Lab: The Hungary-based firm raised $25 million to scale its AI platform that simulates cellular biology to accelerate drug discovery. Global Licensing Surges: Highlighting Chinese expansion, Frontier signed a $1 billion kidney disease deal with GSK, while Harbour BioMed penned a $1.2 billion cancer treatment agreement with Solstice. Astellas & Vir P...